Clinical pharmacokinetics of cefixime: a systematic review

References

• Abdullah A, Mutmainnah M, Wikantyasning ER. 2022. Cocrystals of cefixime with nicotinamide: improved solubility, dissolution, and permeability. Indonesian J Pharm. 33:395–401.
   Web of Science ®Google Scholar
• Asiri YA, Al-Said MS, Al-Khamis KI, Niazy EM, El-Sayed YM, Al-Rashood KA, Al-Yamani MJ, Alsarra IA, Al-Balla SA. 2005. Comparative bioavailability study of cefixime (equivalent to 100 mg/5 ml) suspension (Winex vs Suprax) in healthy male volunteers. Int J Clin Pharmacol Ther. 43(10):499–504.
   PubMed Web of Science ®Google Scholar
• Barbee LA, Nayak SU, Blumer JL, Oʼriordan MA, Gray W, Zenilman JM, Golden MR, Griffiss JM. 2018. A phase 1 pharmacokinetic and safety study of extended-duration, high-dose cefixime for cephalosporin-resistant Neisseria gonorrhoeae in the pharynx. Sex Transm Dis. 45(10):677–683.
   PubMed Web of Science ®Google Scholar
• Barré J. 1989. Pharmacokinetic properties of cefixime. Presse Med. 18(32):1578–1582. fre.
   PubMed Web of Science ®Google Scholar
• Brittain DC, Scully BE, Hirose T, Neu HC. 1985. The pharmacokinetic and bactericidal characteristics of oral cefixime. Clin Pharmacol Ther. 38(5):590–594.
   PubMed Web of Science ®Google Scholar
• Brogden RN, Campoli-Richards DM. 1989. Cefixime. Drugs. 38(4):524–550.
   PubMed Web of Science ®Google Scholar
• Carsenti-Etesse H, Farinotti R, Durant J, Roger PM, De Salvador F, Bernard E, Rouveix B, Dellamonica P. 1998. Pharmacokinetic parameters and killing rates in serum of volunteers receiving amoxicillin, cefadroxil or cefixime alone or associated with niflumic acid or paracetamol. Eur J Drug Metab Pharmacokinet. 23(3):357–366.
   PubMed Web of Science ®Google Scholar
• Choi D-H, Burm J-P. 2007. Bioequivalence evaluation of two brands of cefixime 100 mg capsule (suprax and alpha-cefixime) in Korean healthy volunteers. Biomol Ther. 15(3):182–186.
   Google Scholar
• Cooke A, Smith D, Booth A. 2012. Beyond PICO: the SPIDER tool for qualitative evidence synthesis. Qual Health Res. 22(10):1435–1443.
   PubMed Web of Science ®Google Scholar
• Danafar H. 2015. A quick and easy high performance liquid chromatography method for evaluation of cefixime in human plasma. Pharm Biomed Res. 1(4):29–39.
   Google Scholar
• Danafar H, Hamidi M. 2016. Pharmacokinetics and bioequivalence study of two formulations of cefixime in healthy male volunteers. Iran J Pharm Sci. 12(4):1–14.
   Google Scholar
• Deguchi T, Yasuda M, Yokoi S, Ishida K-I, Ito M, Ishihara S, Minamidate K, Harada Y, Tei K, Kojima K, et al. 2003. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother. 9(1):35–39.
   PubMedGoogle Scholar
• Deng X, Allan-Blitz LT, Klausner JD. 2019. Using the genetic characteristics of Neisseria gonorrhoeae strains with decreased susceptibility to cefixime to develop a molecular assay to predict cefixime susceptibility. Sex Health. 16(5):488–499. eng.
   PubMed Web of Science ®Google Scholar
• Dhib M, Moulin B, Leroy A, Hameau B, Godin M, Johannides R, Fillastre J. 1991. Relationship between renal function and disposition of oral cefixime. Eur J Clin Pharmacol. 41(6):579–583.
   PubMed Web of Science ®Google Scholar
• Dresser J, Wilby KJ. 2021. Safety of single-dose oral cefixime, intramuscular ceftriaxone, or intramuscular gentamicin for the treatment of gonorrhea: a systematic review and meta-analysis. Ann Pharmacother. 55(7):914–920.
   PubMed Web of Science ®Google Scholar
• Duverne C, Bouten A, Deslandes A, Westphal JF, Trouvin JH, Farinotti R, Carbon C. 1992. Modification of cefixime bioavailability by nifedipine in humans: involvement of the dipeptide carrier system. Antimicrob Agents Chemother. 36(11):2462–2467.
   PubMed Web of Science ®Google Scholar
• Ev??Ne E, Brault M, Manche M, Sibille M, Montay G, Vital Durand D. 2001. Bioequivalence study of two formulations (sachet and tablet) of cefixime after single oral doses of 200 mg in healthy male volunteers. Clin Drug Invest. 21(4):287–294.
   Web of Science ®Google Scholar
• Faulkner R, Bohaychuk W, Haynes J, Desjardins R, Yacobi A, Silber B. 1988. The pharmacokinetics of cefixime in the fasted and fed state. Eur J Clin Pharmacol. 34(5):525–528.
   PubMed Web of Science ®Google Scholar
• Faulkner R, Bohaychuk W, Lanc R, Haynes J, Desjardins R, Yacobi A, Silber B. 1988. Pharmacokinetics of cefixime in the young and elderly. J Antimicrob Chemother. 21(6):787–794.
   PubMed Web of Science ®Google Scholar
• Faulkner RD, Yacobi A, Barone JS, Kaplan SA, Silber BM, al. e. 1987. Pharmacokinetic profile of cefixime in man. Pediatr Infect Dis J. 6(10):963–970.
   PubMed Web of Science ®Google Scholar
• Faulkner RD, Bohaychuk W, Desjardins RE, Look ZM, Haynes JD, Weiss AI, Silber BM. 1987. Pharmacokinetics of cefixime after once‐a‐day and twice‐a‐day dosing to steady state. J Clin Pharmacol. 27(10):807–812.
   PubMed Web of Science ®Google Scholar
• Faulkner RD, Sia LL, Barone JS, Forbes SJ, Silber BM. 1989. Bioequivalency of oral suspension formulations of cefixime. Biopharm Drug Dispos. 10(2):205–211.
   PubMed Web of Science ®Google Scholar
• Faulkner RD, Sia LL, Look ZM, Barone JS, Forbes SJ, Weiss AI, Silber BM. 1988. Bioequivalency of solid oral dosage forms of cefixime. Int J Pharm. 43(1–2):53–58.
   Web of Science ®Google Scholar
• Fischer J, Ganellin CR. 2010. Analogue-based drug discovery. Chem Int Newsmag IUPAC. 32(4):12–15.
   Google Scholar
• Guay D, Meatherall R, Harding G, Brown G. 1986. Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency. Antimicrob Agents Chemother. 30(3):485–490.
   PubMed Web of Science ®Google Scholar
• Healy DP, Sahai JV, Sterling LP, Racht EM. 1989. Influence of an antacid containing aluminum and magnesium on the pharmacokinetics of cefixime. Antimicrob Agents Chemother. 33(11):1994–1997. eng.
   PubMed Web of Science ®Google Scholar
• Higgins J. 2011. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration; [updated 2011 March]. www cochrane-handbook org.
   Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JA. 2011. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 343:d5928.
   PubMed Web of Science ®Google Scholar
• Ibraimi Q, Bajrami S, Zenuni A, Aliji A. 2022. Treatment of upper respiratory tract infections with third generation cefalosporine in preschool children. Int J Med Sci. 7(13–14):143–148.
   Google Scholar
• Jabbar EG, Al-Tamimi DJJ, Al-Mahroos MIA, Al-Tamimi ZJJ, Ibraheem JJ. 2021. Pharmacokinetics and bioequivalence study of two formulations of cefixime suspension. J Adv Pharm Educ Res. 11(1):170–177.
   Google Scholar
• Khadam MW, Ashraf MM, Naz U, Bukhari NI, Tahir IM, Asghar D. 2019. Disposition kinetics, renal clearance and urinary excretion of cefixime in adolescent Pakistani boys-DRUG ANALYSIS REPORT. J Pak Med Assoc. 69(3):367–372.
   PubMed Web of Science ®Google Scholar
• Khan A, Iqbal Z, Khan MI, Javed K, Khan A, Ahmad L, Shah Y, Nasir F. 2011. Simultaneous determination of cefdinir and cefixime in human plasma by RP-HPLC/UV detection method: method development, optimization, validation, and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 879(24):2423–2429.
   PubMed Web of Science ®Google Scholar
• Leggett NJ, Caravaggio C, Rybak MJ. 1990. Cefixime. DICP. 24(5):489–495.
   PubMedGoogle Scholar
• Liu P, Müller M, Grant M, Obermann B, Derendorf H. 2005. Tissue penetration of cefpodoxime and cefixime in healthy subjects. J Clin Pharmacol. 45(5):564–569.
   PubMed Web of Science ®Google Scholar
• Liu X, Xie L, Gao J, Lai L, Liu G. 1997. Cefixime absorption kinetics after oral administration to humans. Eur J Drug Metab Pharmacokinet. 22(2):185–188.
   PubMed Web of Science ®Google Scholar
• Long HA, French DP, Brooks JM. 2020. Optimising the value of the critical appraisal skills programme (CASP) tool for quality appraisal in qualitative evidence synthesis. Res Method Med Health Sci. 1(1):31–42.
   Google Scholar
• Mamzoridi K, Kasteridou N, Peonides A, Niopas I. 1996. Pharmacokinetics of cefixime in children with urinary tract infections after a single oral dose. Pharmacol Toxicol. 78(6):417–420.
   PubMedGoogle Scholar
• McLinn SE. 1987. Randomized, open label, multicenter trial of cefixime compared with amoxicillin for treatment of acute otitis media with effusion. Pediatr Infect Dis J. 6(10):997–1001.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. 2010. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 8(5):336–341.
   PubMed Web of Science ®Google Scholar
• Montay G, Masala F, Le Roux Y, Le Liboux A, Uhlrich J, Chassard D, Thebault J, Roche G, Frydman A. 1991. Comparative bioavailability study of cefixime administered as tablets or aqueous solution. Drugs. 42(Suppl 4):6–9.
   PubMedGoogle Scholar
• Nahata MC, Kohlbrenner VM, Barson WJ. 1993. Pharmacokinetics and cerebrospinal fluid concentrations of cefixime in infants and young children. Chemotherapy. 39(1):1–5.
   PubMed Web of Science ®Google Scholar
• Najjar TA, Alkharfy KM, Saad SY. 2009. Mechanism and implication of cephalosporin penetration into oropharyngeal mucosa. J Infect Chemother. 15(2):70–74.
   PubMed Web of Science ®Google Scholar
• Nakashima M, Kanamaru M, Noguchi H, Kajiho T. 1986. Pharmacokinetics of FK027 (cefixime) in healthy volunteers after intravenous injection. Japanese J Clin Pharmacol Ther. 17(3):559–568.
   Google Scholar
• Nakashima M, Uematsu T, Takiguchi Y, Kanamaru M. 1987. Phase I study of cefixime, a new oral cephalosporin. J Clin Pharmacol. 27(5):425–431.
   PubMed Web of Science ®Google Scholar
• Nix DE, Symonds WT, Hyatt JM, Wilton JH, Teal MA, Reidenberg P, Affrime MB. 1997. Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers. Pharmacotherapy. 17(1):121–125.
   PubMed Web of Science ®Google Scholar
• Nord CE, Movin G, Stålberg D. 1988. Impact of cefixime on the normal intestinal microflora. Scand J Infect Dis. 20(5):547–552.
   PubMed Web of Science ®Google Scholar
• Patil S, Hajare AL, Krishnaprasad K. 2014. Open-label, randomized, crossover comparative bioavailability study of cefixime from two tablet formulations after single oral administration. Int J Basic Clin Pharmacol. 3(6):943.
   Google Scholar
• Rubin K, Sullivan D, Sadhasivam S. 2009. Are peripheral and neuraxial blocks with ultrasound guidance more effective and safe in children? Paediatr Anaesth. 19(2):92–96.
   PubMed Web of Science ®Google Scholar
• Sabri NA. 2021. Cefixime and management protocols for COVID-19 second wave. Does its accurate detection in human plasma make sense? Acta Sci Pharm Sci. 5:46–53.
   Google Scholar
• Soliman ABE, Pawluk SA, Wilby KJ, Rachid O. 2022. The use of a modified Delphi technique to develop a critical appraisal tool for clinical pharmacokinetic studies. Int J Clin Pharm. 44(4):894–903.
   PubMed Web of Science ®Google Scholar
• Stone JW, Linong G, Andrews JM, Wise R. 1989. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother. 23(2):221–228.
   PubMed Web of Science ®Google Scholar
• Subiakto Y, Rismawan H, Tuba S. 2022. Quantitative analysis of generic cefixime in healthy subjects using UPLC-MS/MS and its bioavailability and pharmacokinetics evaluation utilization. Res Sq. https://doi.org/10.21203/rs.3.rs-1876303/v1
   Google Scholar
• Tanvir SB, Qasim SSB, Shariq A, Najeeb S, Shah AH. 2018. Systematic review and meta-analysis on efficacy of cefixime for treating gonococcal infections. Int J Health Sci. 12(5):90–100.
   Google Scholar
• Tawfik GM, Dila KAS, Mohamed MYF, Tam DNH, Kien ND, Ahmed AM, Huy NT. 2019. A step by step guide for conducting a systematic review and meta-analysis with simulation data. Trop Med Health. 47:46.
   PubMed Web of Science ®Google Scholar
• Taylor MM, Kara EO, Araujo MAL, Silveira MF, Miranda AE, Branco Coelho IC, Bazzo ML, Mendes Pereira GF, Pereira Giozza S, Bermudez XPD, et al. 2020. Phase II trial evaluating the clinical efficacy of cefixime for treatment of active syphilis in non-pregnant women in Brazil (CeBra). BMC Infect Dis. 20(1):1–15.
   Web of Science ®Google Scholar
• Toyonaga Y. 1997. Pharmacokinetics of antibiotics in children. Acta Paediatr Jpn. 39(1):114–123.
   PubMedGoogle Scholar
• Trenk D, Wagner F, Bechtold H, Nies B, Jähnchen E. 1990. Lack of effect of cefixime on the metabolism of vitamin K1. J Clin Pharmacol. 30(8):737–742.
   PubMed Web of Science ®Google Scholar
• Westphal JF, Jehl F, Schloegel M, Monteil H, Brogard JM. 1993. Biliary excretion of cefixime: assessment in patients provided with T-tube drainage. Antimicrob Agents Chemother. 37(7):1488–1491.
   PubMed Web of Science ®Google Scholar
• Yu RX, Yin Y, Wang GQ, Chen SC, Zheng BJ, Dai XQ, Han Y, Li Q, Zhang GY, Chen X. 2014. Worldwide susceptibility rates of Neisseria gonorrhoeae isolates to cefixime and cefpodoxime: a systematic review and meta-analysis. PLOS One. 9(1):e87849.
   PubMed Web of Science ®Google Scholar
• Zakeri-Milani P, Valizadeh H, Islambulchilar Z. 2008. Comparative bioavailability study of two cefixime formulations administered orally in healthy male volunteers. Arzneimittelforschung. 58(02):97–100.
   PubMed Web of Science ®Google Scholar